Data as of . Holdings from the fund’s latest public SEC N-PORT filing; overlap and active share computed by ETFIQ against the IVV and QQQM books; returns from Tiingo end-of-day prices with distributions reinvested.
LFSC · F/m Emerald Life Sciences Innovation ETF
not published · Themes desk
Open the live card on ETFIQBy weight, 0% of LFSC's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 100%. The top ten holdings are 55% of the fund across 39 positions, as filed for May 31, 2026. Over the year to Sep 4, 2026 the fund returned +61.7% with distributions reinvested against +20.0% for the S&P 500, so a holder was ahead by 41.7 pts.
| Theme (ETFIQ, editorial) | Broad innovation and megatrends |
|---|---|
| Launched | Oct 31, 2024 |
| Already in the S&P 500, by weight (ETFIQ) | 0.0% |
| Active share vs the S&P 500 (ETFIQ) | 100.0% |
| Already in the Nasdaq-100, by weight (ETFIQ) | 0.6% |
| Active share vs the Nasdaq-100 (ETFIQ) | 99.9% |
| Top ten holdings weight | 54.7% |
| Holdings | 39 |
| Net assets (latest filing) | $105M |
| Holdings as of (SEC N-PORT) | May 31, 2026 |
| Top holdings | Travere Therapeutics Inc 7.7%, Cogent Biosciences Inc 7.5%, LivaNova PLC 7.1%, Spyre Therapeutics Inc 6.4%, Guardant Health Inc 5.5%, Mirum Pharmaceuticals Inc 4.9%, Corcept Therapeutics Inc 4.8%, United Therapeutics Corp 4.2%, VeraDermics Inc 3.4%, Savara Inc 3.2% |
| 3 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +21.8% / +4.7% / +17.1 pts / +19.7 pts |
| 6 months: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +33.6% / +15.2% / +18.5 pts / +13.5 pts |
| 1 year: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +61.7% / +20.0% / +41.7 pts / +36.1 pts |
| since launch: total return / S&P 500 / gap / Nasdaq-100 gap (ETFIQ) | +85.3% / +38.2% / +47.1 pts / +35.4 pts |
| Below its all-time high (ETFIQ) | −4.8% |
| Expense ratio (prospectus XBRL) | 0.54% |
| Fee for the part that differs from the S&P 500, active expense ratio (ETFIQ) | 0.54% |
| Closest funds by holdings overlap | HELX 16%, EKG 12%, FMED 11%, GNOM 10% |
Questions people ask
- How much of LFSC is already in the S&P 500?
- By its holdings filed for May 31, 2026, 0% of LFSC by weight is stocks the S&P 500 already holds. Its active share against the index is 100%, so that share is the part doing something different.
- What does LFSC hold?
- 39 positions as filed for May 31, 2026, with the top ten at 55% of the fund. The largest are Travere Therapeutics Inc at 7.7%, Cogent Biosciences Inc at 7.5%, LivaNova PLC at 7.1%.
- Has LFSC beaten the S&P 500?
- Over the year to Sep 4, 2026 LFSC returned +61.7% with distributions reinvested, against +20.0% for the S&P 500, so it finished ahead of the index by 41.7 points.
- What does LFSC cost?
- The prospectus expense ratio is 0.54% a year. Because 100% of the fund differs from the S&P 500, the fee on that differing part works out at 0.54%.
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Funds near this one
Put this on your own page
The difference bar for LFSC, redrawn every trading night. Free to use with the credit link; paste these two lines into any page or newsletter.
<a href="https://etfiq.com/funds/LFSC.html"><img src="https://etfiq.com/embed/themes/LFSC.svg" alt="LFSC difference bar, ETFIQ" width="640"></a>
<p><a href="https://etfiq.com/funds/LFSC.html">LFSC difference bar, updated daily by ETFIQ</a></p>Cite this page. ETFIQ, LFSC on the themes desk, data as of Sep 4, 2026. https://etfiq.com/funds/LFSC.html Free to use with attribution; the underlying files are at Open data.
ETFIQ is an independent publisher of exchange-traded fund data. It is not a fund issuer, broker-dealer or investment adviser, and it makes no recommendations; sort orders and figures are stated arithmetic on published data. Standards · How to read this desk